Usama A Daimee1, Arthur J Moss1, Yitschak Biton1, Scott D Solomon1, Helmut U Klein1, Scott McNitt1, Bronislava Polonsky1, Wojciech Zareba1, Ilan Goldenberg1, Valentina Kutyifa2. 1. From the Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, NY (U.A.D., A.J.M., Y.B., H.U.K., S.M., B.P., W.Z., I.G., V.K.); and Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S.). 2. From the Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, NY (U.A.D., A.J.M., Y.B., H.U.K., S.M., B.P., W.Z., I.G., V.K.); and Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D.S.). Valentina.Kutyifa@heart.rochester.edu.
Abstract
BACKGROUND: We aimed to determine the impact of renal function on long-term outcomes with cardiac resynchronization therapy with defibrillator among patients with mild heart failure (HF). METHODS AND RESULTS: We stratified 1820 Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy patients by QRS morphology into those with and without left bundle-branch block. Subgroups within each QRS morphology category were created based on glomerular filtration rate (GFR): GFR <60 and ≥60 mL/min per 1.73 m(2). Primary end point was death; secondary end points were HF/death and HF events alone during long-term follow-up. Among 1274 left bundle-branch block patients, 413 (32%) presented with GFR <60 (mean, 48.1±8.3) mL/min per 1.73 m(2). Relative to the 861 (68%) patients with GFR ≥60 (mean, 79.6±16.0) mL/min per 1.73 m(2), low-GFR patients experienced higher risk of death (hazard ratio [HR], 2.09; 95% confidence interval [CI], 1.53-2.86; P<0.01) and HF/death (HR, 1.46; 95% CI, 1.17-1.82; P<0.01). In both GFR groups, cardiac resynchronization therapy with defibrillator was associated with reduction in death (GFR <60: HR, 0.66; 95% CI, 0.44-1.00; P=0.05 and GFR ≥60: HR, 0.68; 95% CI, 0.44-1.05; P=0.08) and HF/death (GFR <60: HR, 0.49; 95% CI, 0.36-0.67; P<0.01 and GFR ≥60: HR, 0.50; 95% CI, 0.38-0.66; P<0.01). In the low-GFR group, there was greater absolute reduction in risk of death (GFR <60: 14% and GFR ≥60: 6%) and HF/death (GFR <60: 25 and GFR ≥60: 15%). Among non-left bundle-branch block patients, low GFR predicted outcomes; however, no benefit from cardiac resynchronization therapy with defibrillator was observed. CONCLUSIONS: In patients with mild HF, moderate renal dysfunction is associated with higher risk of death and HF during long-term follow-up. Patients with left bundle-branch block, regardless of baseline renal function, derive long-term benefit from cardiac resynchronization therapy with defibrillator, with greater absolute risk reduction in death and HF among those with moderate renal dysfunction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00180271, NCT01294449, and NCT02060110.
BACKGROUND: We aimed to determine the impact of renal function on long-term outcomes with cardiac resynchronization therapy with defibrillator among patients with mild heart failure (HF). METHODS AND RESULTS: We stratified 1820 Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy patients by QRS morphology into those with and without left bundle-branch block. Subgroups within each QRS morphology category were created based on glomerular filtration rate (GFR): GFR <60 and ≥60 mL/min per 1.73 m(2). Primary end point was death; secondary end points were HF/death and HF events alone during long-term follow-up. Among 1274 left bundle-branch blockpatients, 413 (32%) presented with GFR <60 (mean, 48.1±8.3) mL/min per 1.73 m(2). Relative to the 861 (68%) patients with GFR ≥60 (mean, 79.6±16.0) mL/min per 1.73 m(2), low-GFR patients experienced higher risk of death (hazard ratio [HR], 2.09; 95% confidence interval [CI], 1.53-2.86; P<0.01) and HF/death (HR, 1.46; 95% CI, 1.17-1.82; P<0.01). In both GFR groups, cardiac resynchronization therapy with defibrillator was associated with reduction in death (GFR <60: HR, 0.66; 95% CI, 0.44-1.00; P=0.05 and GFR ≥60: HR, 0.68; 95% CI, 0.44-1.05; P=0.08) and HF/death (GFR <60: HR, 0.49; 95% CI, 0.36-0.67; P<0.01 and GFR ≥60: HR, 0.50; 95% CI, 0.38-0.66; P<0.01). In the low-GFR group, there was greater absolute reduction in risk of death (GFR <60: 14% and GFR ≥60: 6%) and HF/death (GFR <60: 25 and GFR ≥60: 15%). Among non-left bundle-branch blockpatients, low GFR predicted outcomes; however, no benefit from cardiac resynchronization therapy with defibrillator was observed. CONCLUSIONS: In patients with mild HF, moderate renal dysfunction is associated with higher risk of death and HF during long-term follow-up. Patients with left bundle-branch block, regardless of baseline renal function, derive long-term benefit from cardiac resynchronization therapy with defibrillator, with greater absolute risk reduction in death and HF among those with moderate renal dysfunction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00180271, NCT01294449, and NCT02060110.
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Matthew M Kalscheur; Ryan T Kipp; Matthew C Tattersall; Chaoqun Mei; Kevin A Buhr; David L DeMets; Michael E Field; Lee L Eckhardt; C David Page Journal: Circ Arrhythm Electrophysiol Date: 2018-01
Authors: Usama A Daimee; Yitschak Biton; Arthur J Moss; Wojciech Zareba; David Cannom; Helmut Klein; Scott Solomon; Martin H Ruwald; Scott McNitt; Bronislava Polonsky; Paul J Wang; Ilan Goldenberg; Valentina Kutyifa Journal: Ann Noninvasive Electrocardiol Date: 2016-09-15 Impact factor: 1.468
Authors: Márton Tokodi; Walter Richard Schwertner; Attila Kovács; Zoltán Tősér; Levente Staub; András Sárkány; Bálint Károly Lakatos; Anett Behon; András Mihály Boros; Péter Perge; Valentina Kutyifa; Gábor Széplaki; László Gellér; Béla Merkely; Annamária Kosztin Journal: Eur Heart J Date: 2020-05-07 Impact factor: 29.983
Authors: Francisco Leyva; Abbasin Zegard; Robin Taylor; Paul W X Foley; Fraz Umar; Kiran Patel; Jonathan Panting; Charles J Ferro; Shajil Chalil; Howard Marshall; Tian Qiu Journal: Pacing Clin Electrophysiol Date: 2019-04-03 Impact factor: 1.976